Interviews with Pharma and Biotech Global Leaders
Refine Search
Pharmaceutical
US health care giant Johnson & Johnson is set to launch its drug to treat multiple myeloma in 2016, pending regulatory approvals, Peter Lebowitz, head of global oncology, Janssen Pharmaceutical Companies of Johnson & Johnson, told The Pharma Letter in an interview at a London event. 23 October 2015
Biotechnology
Basilea Pharmaceutica plans to start selling isavuconazole in Europe next year at a price modestly higher than the current market leader voriconazole, chief commercial officer David Veitch told The Pharma Letter in an interview. 19 October 2015
Pharmaceutical
"Prolonging life is the gold standard endpoint of any drug trial," Professor John Crown, consultant medical oncologist for St Vincent’s University Hospital told The Pharma Letter in an interview, as the Japanese pharmaceutical giant Eisai announced data for its clinical trials at the European Cancer Congress in Vienna. 30 September 2015
Pharmaceutical
Ferring Pharma is looking at building a commercial as well as manufacturing headquarters in India over the next two-three years, chief operating officer Michael Pettigrew told The Pharma Letter in an interview. 24 September 2015
Pharmaceutical
Ferring Pharma expects a 20% increase in 2015 full-year revenue on the back of a stronger US dollar, chief operating officer Michel Pettigrew, told The Pharma Letter in an interview. 23 September 2015
Biotechnology
MetaCure, the medical technology business focussed on diabetes devices, is looking at annual revenue of $20 million following the roll-out of its flagship product, the company’s founder Professor Shlomo Ben-Haim said in an exclusive interview to The Pharma Letter. 8 September 2015
Biotechnology
Research and drug development collaborations have been a swelling up in the recent months as companies look to pick up strategic partnerships in a bid to expand the base for research. 2 September 2015
Biotechnology
UK drug delivery company SkyePharma has reported robust interim results showing the company’s first half of 2015 operating profits to be 118% ahead year-on-year. 26 August 2015
Pharmaceutical
If all goes according to plan, Merck Serono may be looking at two new drug launches in the cancer segment as soon as end-2016, the company’s R&D chief Luciano Rossetti said in an exclusive interview with The Pharma Letter. 17 August 2015
Pharmaceutical
Rare disease market has renewed interest from the pharma companies as is visible in the heated merger and acquisition activity in the sector. 10 August 2015
Biotechnology
Specialist cancer diagnostic medtech company Angle PLC says its loss for the financial year was “deliberate” as it posted a loss from continuing operations of £3.9 million ($6 million). 24 July 2015
Pharmaceutical
Doctors without Borders/Médecins Sans Frontières (MSF) on Friday called for the removal of access to medicines provisions in the Trans-Pacific Partnership (TPP) trade deal, saying if not checked it could lock out a major chunk of the global population from receiving affordable medicines. 24 July 2015
Pharmaceutical
DS Biopharma is an Ireland-based biopharma drug discovery company aiming to tackle unmet medical needs with a forgotten type of therapy. 14 May 2015
Pharmaceutical
How the issue of affordability is addressed around Europe was discussed at the Association of the British Pharmaceutical Industry’s (ABPI) annual conference in London yesterday. 24 April 2015
Pharmaceutical
The future of R&D and how it can be adapted to improve the affordability of medicines was discussed at the Association of the British Pharmaceutical Industry’s (ABPI) annual conference in London yesterday. 24 April 2015
Pharmaceutical
Affordability of medicines was the topic of the day at the Association of the British Pharmaceutical Industry’s (ABPI) annual conference in London today. 23 April 2015
Biosimilars
German family-owned drug major Boehringer Ingelheim has been in the biosimilars business since the end of 2011, when it developed what was effectively a startup within the company to manufacture a new kind of therapy. What it now has in 2015 is a portfolio of biosimilar products, three of which are in Phase III. 2 March 2015
Pharmaceutical
In the opening sessions at the Genesis One Nucleus 2014 conference in London yesterday, the main themes and areas of interest were outlined as personalized medicine economics and big data health innovation. 10 December 2014
Pharmaceutical
With so many balls to juggle in the development pathway of a new drug, pharma companies looking for support along the research process often find value in calling upon the expertise of contract research organizations. 8 December 2014
Pharmaceutical
In one of the opening sessions, cloud-based life sciences provider Veeva’s co-founder and president Matt Wallach asserted that “transparency will force you to understand your cause better, and that will be good for the industry.” 5 December 2014
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze